Skip to content

Clinical trial on Women health PCOS conditions

A Prospective, Randomized, Open Label Study to Evaluate the Safety And Efficacy Of Mulmina Orange Amla Ready to Drink as a Supplement In Women With PCOS

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/033101
Enrollment
60
Registered
2021-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Mulmina Amla Orange ready to drink: Dose: 200ml drink Dosage form: Oral Drink Frequency : 2 packs per day for 4 weeks Route of administrate : Orally Control Intervention1: Standard of C

Sponsors

Jagdale industries pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Female volunteer aged more than 18 years ii. Women with mild PCOS related complications iii. Willing to give written consent to participate

Exclusion criteria

Exclusion criteria: 1. Patients with preexisting severe systemic disease necessitating long term medication. 2. Patients with known history of diabetes mellitus. 3. Evidence of significant uncontrolled comorbid disease which in the investigators opinion would jeopardize patient participation. 4. History of cancer including solid tumors hematologic malignancies and carcinoma in situ 5. Any neurological congenital or acquired vascular or systemic disorder which could affect any of the efficacy assessments. 6. Participation in the current or previous treatment with any approved or investigational health supplements during the past 1 month.

Design outcomes

Primary

MeasureTime frame
Overall improvement in the PCOD condition from baselineTimepoint: Day 0, 14 and 28

Secondary

MeasureTime frame
General health and adverse eventsTimepoint: Day 0 to Day 28

Countries

India

Contacts

Public ContactMr Raghavendra K V

Radiant Research Services Pvt. Ltd

ashok@radiantresearch.in9880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026